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Poster Session II S311preliminary results from an IRB-approved prospective, open label,
phase II trial to test the efficacy of montelukast, a leukotriene in-
hibitor, for the treatment of BOS after HSCT. BOS diagnostic
criteria included: FEV1\75%, FEV1/VC\0.7 or air trapping
on CT and RV. 120% or RV/TLC. 120% in the absence of in-
fection and presence of another cGVHD manifestation. Eleven
patients have enrolled to date. One withdrew prior to medication
initiation and 9/10 are currently on study medication (10 mg mon-
telukast po nightly). Patient characteristics include age range
15-60 years, 7/11 female, baseline FEV1 range from 33 to 71%
predicted, and 3/11 patients requiring oxygen supplementation.
Sixty-four % (7/11) have reached the primary endpoint (6 months
of study drug). FEV1 increased by 6-10% predicted in 3 patients,
remained stable in 3, and declined by less than 15% in 1. Slope of
the FEV1 value generated as linear regression of FEV1 volume vs.
days post-transplant revealed: 5/7 increase in slope, 2/7 decrease
in slope from pre-study FEV1 values. Three patients had immu-
nosuppression reduced during this time period with complete ces-
sation of tacrolimus in 1, cessation of steroids in 1, and decreased
tacrolimus in 1(including 2 with stable FEV1 and 1 with increase
in FEV1); 1 patient had an increase in steroid dose less than 1 mg/
kg/day. Two patients had worsening of other cGVHD manifesta-
tions on study, including a skin flare that resolved without increas-
ing systemic therapy (1) and gastrointestinal cGVHD flare that
improved with increased steroids including local therapy (1). Mon-
telukast was well-tolerated with one grade II attributable adverse
event (insomnia) during the six-month collection period.
Improvements were also noted in oral mucosa cGVHD manifesta-
tions in 3/7 and liver in 2/7. These preliminary findings suggest
that montelukast may have a role in the therapy of BOS after
allogeneic HSCT.417
POMALIDOMIDE (POM) IN ADVANCED CORTICOSTEROID-RESISTANT
CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Pusic, I.1, DiPersio, J.F.1, Goran, S.L.1, Romvari, E.M.1, Bauer, S.L.1,
Comer, H.S.1, Abboud, C.N.1, Cashen, A.F.1, Gale, R.P.2 1Washington
University School of Medicine, Siteman Cancer Center, St. Louis, MO;
2Celgene Corporation, Summit, NJ
Background: Thalidomide is active in cGVHD, but with trouble-
some side effects such as neutropenia, neuropathy and somnolence.
POM is a member of the new class of immune-modulating drugs
(IMiD) .100-fold more potent than thalidomide in inhibiting
production of TNFa and increasing Th1-cells. We assessed effi-
cacy and safety of POM in people with corticosteroid-resistant
cGVHD.
Methods: Subjects had to have moderate (N5 2) or severe
(N5 6) cGVHD (NIH criteria), and failed prednisone (0.5 mg/
kg/d for .8 w) and/or 2nd-line immune-suppression. No ECP
in the preceding 3 m or new therapy in the preceding 1 m was al-
lowed. POM was given by mouth at a starting dose of 3 mg/d with
dose-reduction to 2, 1, and 0.5 mg/d for intolerance or adverse
events. Subjects were evaluated for response every 3 m. Responses
were assessed based upon changes in signs or symptoms of each
organ system and overall response was than determined using
NIH Criteria.
Results: 8 subjects are enrolled so far. Median time posttransplant is
2.9 y (1.5-6 y), median time since diagnosis of cGVHD is 1.8 y (1-4.5
y), 4 subjects received related- and 4 unrelated-allotransplants; 5 had
prior acute GVHD. Median N of prior systemic cGVHD therapies
was 3 (2-5). Affected organs included skin (N5 8), mouth (N5 8),
eye (N5 7), GI (N5 5), musculo-skeletal (N5 4), liver (N5 2),
genital (N5 2) and lung (N5 2). Median KPS was 80%. 7 subjects
required dose-reductions for muscle cramps, tremors and/or fatigue.
There was no bonemarrow suppression, neuropathy, somnolence or
thrombosis. 5 subjects discontinued therapy: 1 for worsening skin
andmouth lesions, 3 for no response (2 had worsening tremors, mus-
cle cramps and fatigue) and 1 for worsening pain. 1 subject died of
a heart attack 4 m after stopping POM. 3 subjects completed 6 m
of therapy and underwent 2nd response evaluation: 2 at 2 mg/d
and 1 at 1 mg/d. 2 have a complete response (CR) and 1 a partial re-
sponse (PR) of erythematous skin changes and aCR ofGI symptoms.There are ongoing improvements\PR in skin, mouth, and eyes. 3
subjects have a global PR.
Conclusion: POM can be given for corticosteroid-resistant
cGVHD without toxicities that limit use of thalidomide in this
context. Our data suggest POM is active in moderate/severe corti-
costeroid-resistant cGVHD. 3 mg/d is likely a too high starting
dose: we recommend 1-2 mg/d in future studies. Subject accrual
continues, as do correlative laboratory studies; these data will be
reported.418
A PROSPECTIVE STUDY OF DONOR IMMUKNOW AS A BIOMARKER FOR
ACUTE GVHD IN HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS
Kang, Y.1, DeOliveira, A.2, Peel, L.E.2, Chen, D.-F.2, Chao, N.1 1Duke
University Medical Center, Durham, NC; 2Duke University Medical
Center, Durham, NC
Introduction:Graft versus host disease (GvHD) occurs in40% of
allogeneic hematopoietic cell transplantation (HCT) recipients and
is associated with substantial morbidity and mortality. Immunolog-
ical parameters of donor cells that predispose a recipient to GvHD
will be of great value. The Cylex ImmuKnow assay determines
the strength of immune function by quantifying the amount of
ATP released from phytohemagglutinin-stimulated peripheral
bloodCD4+ cells. In our current study, we utilized the ImmuKnow
to assess whether a donor’s immune response correlates with early
outcomes in recipients post-HCT.
Patients and Methods: Twenty-six (26) donor-recipient pairs were
included in our study (15 HLA identical siblingHCT and 11 haploi-
dentical HCT). Recipients received an average cell-dose of
10.76 4.9  106 CD34+ cells/kg. Blood samples obtained prior to
G-CSFmobilization and prior to stem cell collection (approximately
2 weeks apart) were assayed for ImmuKnow values and cell counts
(WBC, ANC, ALC & CD34+ count).
Results:G-CSF mobilization led to a significant increase in Immu-
Know ATP values from 342 to 728 ng/mL (p\0.001) along with
an increase in all measured cell counts. Grade$ II acute GvHD oc-
curred in 27% of haploidentical HCT recipients (3/11 patients)
and 20% of HLA identical HCT recipients (3/15 patients). In hap-
loidentical HCT, mobilized donor blood ImmuKnow ATP
values did not correlate with GvHD. However, donor Immu-
Know values correlated with increased risk of acute GvHD in
HLA identical sibling HCT. In HLA identical sibling HCT,
ATP values in excess of 747 ng/mL predicted grade II or higher
GvHD with a likelihood ratio of 4.00 (2.9-5.5, 95% confidence),
sensitivity of 100%, and specificity of 75% (AUC5 0.889,
p5 0.003).
Conclusions: If confirmed in larger studies, these data suggest that
ImmuKnow can serve as an independent predictor/biomarker for the
development of GvHD in HLA identical HCT.419
MYCOPHENOLATE MOFETIL AS THERAPY FOR STEROID DEPENDENT OR
REFRACTORY GRAFT VERSUS HOST DISEASE: TEN YEARS EXPERIENCE
FROM A SINGLE CENTER IN BRAZIL
Nunes, E.C., Funke, V.A.M., Setubal, D.C., Medeiros, L.A.,
Oliveira, M.M., Bonamin, C., Nabhan, S., Bitencourt, M.A.,
Ribeiro, L., Morando, J., Bonfim, C., Vieira, A.G., Franco, V.,
Loth, G., Pasquini, R., Neto, J.Z. Hospital de Clinicas-Federal University
of Parana, Curitiba, Parana, Brazil
Chronic graft-versus-Host-Disease (GVHD) is observed in up to
50% of long term survivors of hematopoietic stem cell transplants
(HSCT) and is associated to important morbidity and mortality.
Mycophenolate Mofetil (MMF) has been used as therapy for refrac-
tory chronicGVHDwith good efficacy and tolerability.We describe
our experience at Hospital de clınicas of Federal University of Par-
ana-Brazil during the last ten years on the use of this drug as rescue
for refractory chronic GVHD.
Diagnosis acute GVHD chronic GVHD Previous therapy
FA Skin, gut Skin, gut, eye ,liver CTC/ CSA/ basiliximab
FA Gut, stomach Mouth, liver CTC/ CSA/ basiliximab
MDS skin skin, mouth CTC/ CSA/ AZA
MDS (second
ECP cycle)
skin CTC/ CSA/ AZA
AAS skin Skin, liver, lung CTC/ CSA/ basiliximab
FA Skin, gut, liver Skin, gut, liver CTC/ CSA /basiliximab/
MMF/Tacrolimus
ALL Skin Mouth, skin, liver, eye CTC/CSA
CML skin, liver Skin, eye, stomach,
liver, mouth, fascia
CTC/ CSA/ MMF
BDA Skin, eye,
mouth
CTC/ CSA/ basiliximab
SCID skin Skin, gut, liver CTC/ CSA/ basiliximab/
AZA/ Tacrolimus
IFN gama
deficiency
Skin, eye,
mouth
CTC/ CSA/ basiliximab
CML Skin, eye Skin, lung, eye, mouth CTC/ CSA
FA Skin, eye Skin, fascia, eye CTC/ CSA/
S312 Poster Session IIWe retrospectively analysed 22 patients (10 females e 12 males)
who received HSCT between 01/1999 and 01/2009 and devel-
oped as complicattion chronic GVHD steroid refractory or de-
pendent and who received MMF as second line therapy.
Diagnosis: Fanconi Anemia (8); Chronic Myeloid Leukemia(5);
Others(9). Cell source was marrow in 16, pheripheral blood
(pb) in 3, and cord blood in 3 patients. Eight patients received
HSCT from related and 14 from unrelated donors. Immunopro-
phylaxis was: CSA e methotrexate (MTX) (15); CSA e CTC(2);
CSA, MTX and methylprednisolone (5). All patients had exten-
sive chronic GVHD. As we reclassified them according to the
NIH consensus criteria, 15 (68%) of them had severe disease
and 7(39%) had moderate disease. Thirteen (59%) had progres-
sive, 8 (36%) had ‘‘de novo’’ and 1 (5%) quiescent GVHD. Liver,
oral mucosa and skin were the sites most frequently envolved.
Nine patients had more than 3 organs involved, 6 were using ste-
roids at the time of diagnosis and 5 had thrombocytopenia lower
than 100.000/mm3. Overall response defined by improvement in
at least one organ or estabilization of GVHD was observed in 15
(68%) patients. Eleven patients (50%) stopped steroids after a me-
dian of 16.5 months. Eight patients (36%) stopped all immunesu-
pression in a median time of 43 months. Four patients died for
reasons related to their GVHD and 3 others received another
drug for failure with MMF. We did not observe grade 2-4 toxicity
leading to suspension of the drug.
In conclusion MMF was a safe drug as therapy for chronic steroid
dependent or refractory GVHD with an overall response of 68% in
this population. Prospective trials are necessary for a better evalua-
tion of the efficacy of this drug as second line therapy for chronic
graft-versus-host-disease.basiliximab/ PUVA/
Tacrolimus/ MMF
CML skin Skin, mouth, eye, liver CTC/ CSA/ thalidomide/
AZA/ MMF
JMML Skin,
gastrointestinal
tract
CTC/ CSA/ basiliximab
CML Skin, liver Mouth, eye, liver CTC/ CSA/ Tacrolimus
AF: Fanconi anemia, SMD:myelodysplastic syndrome; AAS: severe aplas-
tic anemia; LLA: acute lymphoblastic leukemia LMC: chronic myeloid
leukemia, ABD: Diamond-Blackfan anemia, SCID: severe combined im-
munodeficiency, JMML: juvenile chronic myelomonocytic leukemia,
AZA: azathioprine; MMF: mycophenolate mofetil.420
EXTRACORPOREAL PHOTOPHERESIS IN REFRACTORY ACUTE AND/OR
CHRONIC GRAFT VERSUS HOST DISEASE AFTER ALLOGENEIC STEM
CELL TRANSPLANTATION
Franco, V., Funke, V.A.M., Nunes, E.C., Setubal, D.C., Medeiros, L.,
Michels, M., Bonamin, C., Nabhan, S., Ribeiro, L., Morando, J.,
Bitencourt, M., Bonfim, C., Vieira, A.G., Loth, G., Pasquini, R.,
Neto, J.Z. Hospital de Clinicas-Federal University of Parana, Curitiba,
Parana, Brazil
Introduction:Graft- versus-host disease (GVHD) after hematopoi-
etic stem cell transplantation (HSCT) is associated with high mor-
bidity and mortality rates. Corticosteroids and calcineurin
inhibitors are the first line treatment of GVHD.There are many sec-
ond line therapies with few controlled studies. Extracorporeal Pho-
topheresis (ECP) is an immunomodulatory treatment which has
recently been proof as steroid sparing procedure (Flowers et al,
Blood. 2008 Oct 1;112(7):2667-74)
Objective:We describe our experience at the Hospital de Clınicas
from the Federal University of Parana- Brazil, with ECP in pa-
tients with steroid refractory or dependent acute or chronic
GVHD.
Patients andMethods:We reviewed between Februray 2002 and
June, 2009, the data of 19 patients who received allogeneic he-
matopoietic stem cell transplantation (HSCT) and developed
as complication acute and/or cronic GVHD refractory to corti-
costeroids and cyclosporine therapy and were then treated with
ECP (20 procedures: one patient had been submitted twice).
Four patients were excluded because they had received less
than six sessions; fifteen patients were evaluated (female:13
male:2). The mean age at HSCT was 11 years (range 3 to 49).
Partial response was defined by an improvement in at least one
involved organ and complete response as resolution of all symp-
toms of GVHD. The clinical characteristics of these patients are
in Table 1.
Results:Median overall survival afterHSCTwas 2 years (range 3 m-
13y). Five patients were submitted to ECP due to acute GVHD and
13 due to chronic GVHD (2 patients had overlap syndrom
GVHD.Three of 5 patients with acute GVHD (60%) had total re-
sponse, 1 (20%) partial response and 1 (20%) had no response.
Nine of 13 patients with chronic GVHD (70%) had partial response,
2 (15%) total response and 2 (15%) had no response. Ten patients(67%) reduced the dosage of corticosteroid to less than 0,5 mg/kg/d.
There were no severe adverse effects related to ECP.
Conclusion: ECP is an effective alternative in the treatment of
GVHD in this study, with no severe adverse effects observed. The
procedure allowed reduction of corticosteroids in 67% of our pa-
tients. Prospective trials are necessary for a more precise evaluation
of this procedure in GVHD therapy.421
SOLUBLE HUMAN LEUKOCYTE ANTIGEN G (SHLA-G) IN HEMATOPOIETIC
CELL TRANSPLANTATION IS ASSOCIATED WITH SEVERAL CLINICAL
COMPLICATIONS AFTER TRANSPLANT
Waterhouse, M., Duque-Afonso, J., Samek, E., Bertz, H., Finke, J.
Freiburg University Medical Center, Freiburg, Baden Wuettemberg,
Germany
HLA-G is a non classical class I HLA molecule with low level of
polymorphisms and with 7 isoforms, 4 are membrane bound and 3
are soluble. Another differential characteristic is it is tissue restricted
and have been described in adult thymic medulla, cornea, pancreatic
islet and endothelial cell precursors. Several immune modulatory
functions have been attributed to this molecule such as the interac-
tion between B, T,NK and antigen presenting cells. Due to their im-
munomodulatory properties we investigated the possible role of
soluble HLA-G (sHLA-G) in the allogeneic hematopoietic cell
transplantation (HCT) setting. A cohort of 37 patients, who under-
went HCT, were studied, 13 patients had acute myeloid leukemia, 8
patients had myelodisplastic syndromes (preleukemia disease) while
the rest of the patients had non myeloid malignancies. Twenty eight
patients received reduce intensity conditioning regimen, while the
rest of the patients received myeloablative conditioning treatment.
Plasma samples from all patients were obtained before the condition-
ing regimen and after transplant at different timepoints. Soluble
HLA-G concentration was measured in duplicates of plasmas by
a specific enzyme-linked immunosorbent assay (ELISA) using the
MEMG/9 as the capture antibody. Pre transplant variables were
age, gender, disease, type of transplant (related, unrelated), infused
marrow cell dose and donor gender. Post transplantation variables
